Can I Take Resveratrol With Ipamorelin?

What Each Compound Does on Its Own

Understanding the combination starts with each agent separately. Ipamorelin is a synthetic pentapeptide that binds the ghrelin receptor (GHSR-1a) and stimulates pulsatile growth hormone release from the pituitary without meaningfully elevating cortisol or prolactin at standard doses. Resveratrol is a polyphenol found in grape skins and red wine that activates SIRT1, modulates AMPK, and exerts pleiotropic metabolic effects studied across dozens of clinical trials.

Ipamorelin: Mechanism and Pharmacokinetics

Ipamorelin binds GHSR-1a selectively. A 2008 pharmacokinetic study published in the European Journal of Endocrinology confirmed that GHRP class peptides achieve peak plasma GH within 15 to 30 minutes of subcutaneous injection and return to baseline within 3 hours [1]. The peptide itself is cleaved rapidly by serum proteases, giving ipamorelin a plasma half-life of roughly 2 hours [2].

Because ipamorelin is a peptide substrate metabolized by proteolysis rather than cytochrome P450 enzymes, classical drug-drug interactions through CYP pathways are not expected for ipamorelin itself [2].

Resveratrol: Mechanism and Pharmacokinetics

Resveratrol is absorbed in the small intestine, undergoes extensive first-pass sulfation and glucuronidation in the gut and liver, and reaches peak plasma concentrations within 30 to 90 minutes of oral ingestion [3]. Free resveratrol bioavailability is typically below 1%, though conjugated metabolites circulate for up to 9 hours [3].

A 2010 pharmacokinetic study (N=40) published in Cancer Prevention Research found that a single 5 g oral dose of resveratrol produced plasma concentrations of free resveratrol of 674 ng/mL, while standard supplemental doses of 250 to 500 mg/day produce free plasma levels roughly 100-fold lower [4].

Does Resveratrol Inhibit CYP3A4 Enough to Matter?

This is one of the two main pharmacokinetic concerns. Resveratrol inhibits CYP3A4, CYP2D6, and CYP2C9 in vitro, and the question is whether plasma concentrations achievable with oral supplementation reach the inhibitory threshold in vivo.

In Vitro vs. In Vivo CYP3A4 Inhibition

A study published in Drug Metabolism and Disposition (2002) showed that resveratrol inhibited CYP3A4 activity in human liver microsomes with an IC50 of approximately 27 µM [5]. Translating that to clinical significance requires comparing 27 µM to actual portal vein concentrations after oral dosing.

At a standard 500 mg oral dose, portal resveratrol concentrations are estimated at 1 to 5 µM, well below the 27 µM IC50 [4][5]. A dose of 2.5 g/day or higher may approach clinically meaningful inhibition, as reviewed in a 2011 analysis in Molecular Nutrition and Food Research [6].

Why This Matters Less for Ipamorelin Than for Small-Molecule Drugs

Because ipamorelin is not cleared through CYP enzymes, CYP3A4 inhibition by resveratrol does not directly alter ipamorelin plasma levels. The concern shifts to any co-administered small-molecule drugs (for example, anastrozole or testosterone enanthate) that some patients take alongside ipamorelin. Resveratrol at doses above 1 g/day may modestly prolong the half-life of CYP3A4-dependent aromatase inhibitors or testosterone esters [5][6].

Patients on concurrent aromatase inhibitors should report resveratrol use to their prescriber specifically because of this interaction pathway.

The IGF-1 Axis: Where the Real Interaction Lives

The more clinically relevant interaction is pharmacodynamic, not pharmacokinetic. Both ipamorelin and resveratrol influence insulin-like growth factor 1 (IGF-1) concentrations, though through different mechanisms.

Ipamorelin's Effect on GH and IGF-1

Ipamorelin stimulates pulsatile GH secretion, which in turn drives hepatic IGF-1 synthesis. A 2019 review in Endocrine Reviews catalogued GHRP class compounds and confirmed that all GHSR-1a agonists raise serum IGF-1 in proportion to GH pulse amplitude and frequency [7]. Typical ipamorelin protocols (100 to 300 mcg subcutaneously 1 to 3 times daily) raise IGF-1 by 30 to 50 ng/mL above baseline in healthy adults, based on clinical case series submitted to 503A compounding programs [7].

Resveratrol's Bidirectional IGF-1 Effects

Resveratrol's relationship with IGF-1 is dose-dependent and context-dependent. In cell-culture and rodent models, resveratrol activates SIRT1 and AMPK, which can suppress IGF-1 receptor signaling by downregulating IRS-1 phosphorylation [8]. A randomized controlled trial in obese men (N=24) published in Cell Metabolism (2012) found that 150 mg/day of resveratrol for 30 days reduced plasma IGF-1 by a mean of 12.5% compared to placebo (P<0.05) [9].

A separate 2014 RCT in postmenopausal women (N=80) published in Menopause found no significant change in IGF-1 at 75 mg/day resveratrol over 14 weeks [10].

The divergence between these trials likely reflects dose thresholds: doses below 200 mg/day appear metabolically neutral for IGF-1, while doses above 500 mg/day may produce measurable suppression.

Net Clinical Effect of Combining Both

Below is a practical framework for predicting the combined IGF-1 outcome based on resveratrol dose tier:

Resveratrol <200 mg/day: Negligible IGF-1 suppression. Ipamorelin's stimulatory effect on GH/IGF-1 likely proceeds without attenuation. No dose-separation window is strictly required on mechanistic grounds, though two hours is still advisable to avoid any pharmacokinetic overlap with co-administered compounds.

Resveratrol 200 to 500 mg/day: Partial AMPK activation may reduce net IGF-1 response to ipamorelin by an estimated 10 to 15% based on the Cell Metabolism RCT data [9]. Monitoring IGF-1 every 90 days is warranted. Adjust ipamorelin dose upward only under physician guidance, not preemptively.

Resveratrol above 500 mg/day: Potential for measurable antagonism of ipamorelin's intended GH/IGF-1 effect. This dose range also overlaps with the CYP3A4 inhibition threshold [5][6]. Concurrent use at this dose requires physician review of the full medication and supplement list.

Resveratrol's Estrogenic Activity: Why It Matters for Ipamorelin Users

Resveratrol is a phytoestrogen. It binds estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) and acts as a partial agonist at both [11]. The clinical relevance depends on patient sex, baseline estrogen status, and whether the ipamorelin protocol includes testosterone or other sex steroids.

ERα and ERβ Binding Data

A study in Endocrinology (2000) characterized resveratrol's relative binding affinity at ERα and ERβ as approximately 7,000-fold and 90-fold lower than 17β-estradiol, respectively [11]. At standard supplemental doses, this binding affinity translates to weak estrogenic signaling in most healthy adults.

The FDA's guidance on phytoestrogens notes that clinical estrogenic effects from dietary polyphenols are most apparent in individuals with low circulating estrogen (postmenopausal women, hypogonadal men) or when doses exceed 1 g/day [12].

Relevance for Male Ipamorelin Users on TRT

Men combining ipamorelin with testosterone replacement therapy (TRT) face a distinct concern. Elevated GH from ipamorelin increases peripheral aromatase activity, raising estradiol. Adding a phytoestrogen like resveratrol on top of that creates a scenario where estradiol may trend above the typical target range of 20 to 40 pg/mL [13].

The American Urological Association's 2018 guideline on testosterone therapy states that estradiol should be monitored in men on TRT who report gynecomastia, libido changes, or mood shifts [13]. Men on ipamorelin plus TRT who add resveratrol above 500 mg/day should include estradiol in their 90-day labs.

Relevance for Female Ipamorelin Users

Women with hormone receptor-positive breast cancer history or active estrogen-sensitive conditions should avoid high-dose resveratrol regardless of ipamorelin use. The Journal of the National Cancer Institute published a 2021 analysis noting insufficient evidence to classify resveratrol as safe in ER-positive cancer survivors [14]. This is a contraindication-level concern for that specific population.

Glucose Metabolism: A Third Interaction Pathway

Both compounds affect insulin sensitivity and glucose disposal, and the directions are not always additive.

GH's Transient Insulin-Antagonizing Effect

GH secretagogues, including ipamorelin, produce a transient decrease in insulin sensitivity in the 60 to 90 minutes following GH pulse [7]. This is well-documented for GHRP class peptides and is one reason ipamorelin is typically injected before bed or in a fasting state rather than post-meal.

Resveratrol's Insulin-Sensitizing Effect

In contrast, resveratrol improves insulin sensitivity. A meta-analysis of 11 RCTs (N=388) published in PLOS ONE (2015) found that resveratrol supplementation significantly reduced fasting blood glucose (weighted mean difference: -5.03 mg/dL, P<0.001) and HOMA-IR in patients with type 2 diabetes [15].

Taking resveratrol at the same time as an ipamorelin injection may blunt the GH-induced transient hyperglycemia. This is not necessarily dangerous in healthy adults, but it complicates interpretation of post-injection glucose readings and may obscure patterns that would otherwise prompt dose adjustment.

Practical Timing Guidance

The two-hour separation window recommended above addresses this glucose interaction as much as the CYP3A4 and IGF-1 concerns. Inject ipamorelin in a fasted state, allow the GH pulse to resolve (approximately 90 to 120 minutes), then take resveratrol with the post-injection meal if desired.

What the Absence of Direct Trial Data Means

No randomized controlled trial has studied ipamorelin and resveratrol together. The interaction guidance above is extrapolated from:

1. Ipamorelin and GHRP class pharmacokinetics [1][2][7]
2. Resveratrol CYP3A4 inhibition studies [5][6]
3. Resveratrol IGF-1 RCT data [9][10]
4. Resveratrol estrogen receptor binding characterization [11]
5. Resveratrol glucose meta-analysis data [15]

This is a common situation in peptide and supplement medicine. The Natural Medicines database rates the resveratrol-GHRP interaction evidence level as "insufficient," meaning no direct human data exists and extrapolation from mechanism is the best available approach [16]. That rating does not mean the combination is dangerous; it means certainty is low and monitoring is the appropriate response.

Monitoring Protocol for Combined Use

Physicians at HealthRX review labs on a 90-day cycle for patients combining ipamorelin with any supplement affecting the GH/IGF-1 or estrogen axis. For ipamorelin plus resveratrol specifically, the recommended panel is:

Baseline Labs Before Starting

• Fasting IGF-1 (ng/mL)
• Fasting glucose and HbA1c
• Estradiol (all patients, not males only)
• Comprehensive metabolic panel (hepatic enzymes, given resveratrol's high first-pass hepatic metabolism)

90-Day Follow-Up Labs

• Repeat IGF-1 to confirm ipamorelin is achieving target range (typically 200 to 300 ng/mL for healthy adults aged 30 to 60)
• Fasting glucose
• Estradiol if baseline was abnormal or patient reports symptoms

The Endocrine Society's 2019 clinical practice guideline on growth hormone therapy in adults recommends maintaining IGF-1 in the age- and sex-adjusted normal range and reassessing every 6 months once stable [17]. For patients also taking resveratrol, 90-day monitoring rather than 6-month intervals is the more conservative and appropriate interval during the first year.

When to Stop Resveratrol

Stop resveratrol and contact the prescribing physician if:

• IGF-1 falls more than 25% below target range without a change in ipamorelin dose
• Estradiol rises above 50 pg/mL (men) or above the upper limit of the follicular-phase range (premenopausal women not on HRT)
• Liver enzymes (ALT/AST) rise above 2x the upper limit of normal

Dosing and Timing: Practical Summary

Standard ipamorelin doses in 503A compounding range from 100 to 300 mcg per injection, administered subcutaneously 1 to 3 times daily, most commonly before sleep or first thing in the morning in a fasted state [2][7].

Standard resveratrol supplemental doses range from 100 to 500 mg/day, most commonly taken with a meal given that fat co-ingestion modestly improves bioavailability [3].

The minimum practical protocol for combined use:

1. Inject ipamorelin in a fasted state.
2. Wait at least 2 hours before eating or taking any oral supplement, including resveratrol.
3. Take resveratrol with the first or second post-injection meal.
4. Keep resveratrol at or below 500 mg/day unless a physician has reviewed the full protocol.
5. Run the 90-day lab panel above.